The Biotech Reckoning: Why 2026 is Defining a New Era for Medical InnovatorsGlobal Report·Aug 25 at 06:33 AMAMGN-1.05%REGN-1.67%
Cross-Border Realignments: How 7 US Biopharma Players Are Navigating Global Regulatory TensionsGlobal Report·Aug 25 at 04:21 AMBEAM-3.81%IONS-2.21%
Cross-Border Bets and Delisting Clocks: Micro-Cap Biotech Fractures Under Liquidity SqueezeGlobal Report·Aug 19 at 05:12 AMBIYA-5.51%ADTX+17.24%
The Great Healthcare Crossover: SK’s AI Compute Play and Micro-Cap SpinoffsGlobal Report·Aug 16 at 05:13 AMSKHY-0.35%ADTX+17.24%
The Overlooked Summer Shakeups: Spinoffs, FDA Drama, and Insider BetsGlobal Report·Aug 4 at 04:17 AMTRIP+0.82%SRPT-3.38%
The 2026 Biotech Reckoning: Enough With the AI Hype, Show Me the EfficacyGlobal Report·Aug 2 at 04:12 AMGENB-2.79%IBRX-4.17%
Macro Signals Across the Microstructure: What a Diverse Basket Says About Capital FlowsGlobal Report·Jul 30 at 04:13 AMWMB-0.62%EWBC-0.16%
US Biotech Sector Nears Commercialization Inflection Point on Key FDA ApprovalsGlobal Report·Jul 29 at 04:19 AMCRSP-2.78%GENB-2.79%
Capital Shifts Across US Small-Caps: Navigating Bitcoin Treasuries and Biotech MilestonesGlobal Report·Jul 28 at 04:12 AMRSKD+3.10%ADVB+1.36%
Niche Market Moves: Major Overhauls From Energy to AI InfrastructureGlobal Report·Jul 22 at 04:17 AMWLLBW0.00%BMEA+2.98%
The Unbundling of the Long Tail: Strategic Realities in a Post-ZIRP MarketGlobal Report·Jul 18 at 04:13 AMLDOS+0.57%DPRO+2.17%
Aditxt Amends Note Purchase Pact to Add Investor, Swap Notes With No Change in PrincipalTradingView·Jul 17 at 11:13 AMADTX+17.24%
